Thomas Burns
Vermogen: 2 M $ op 31-05-2026
Vermogen: 2 M $ op 31-05-2026
Thomas M.
Burns is currently a Non-Executive Director at LAVA Therapeutics NV since 2025.
Formerly, Mr. Burns was an Independent Director at Acorda Therapeutics, Inc. from 2023 to 2024 and served as Chief Financial Officer & Senior VP-Finance at XOMA Royalty Corp.
from 2015 to 2026.
Education includes an MBA from Golden Gate University conferred in 1999 and an undergraduate degree from Santa Clara University conferred in 1995.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-03-2026 | 36.209 ( 0,29% ) | 2 M $ | 31-05-2026 | |
| 19-09-2025 | 2.000 ( 0,2% ) | 50 910 $ | 31-05-2026 | |
| 19-09-2025 | 2.000 ( 0,11% ) | 50 680 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Directeur/Bestuurslid | 07-11-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| XOMA ROYALTY CORPORATION | Financieel Directeur/CFO | 12-01-2026 |
| ACORDA THERAPEUTICS, INC. | Directeur/Bestuurslid | 21-08-2024 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
XOMA Royalty Corp.
XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops, manufactures and markets therapeutic products for neurological disorders | Health Technology |
Golden Gate University
Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santa Clara University
Santa Clara University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAVA Therapeutics NV
LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau